Breaking News Instant updates and real-time market news.

AET

Aetna

$177.00

1.25 (0.71%)

, CVS

CVS Health

$68.64

0.41 (0.60%)

13:25
02/27/18
02/27
13:25
02/27/18
13:25

House Judiciary Committee to hold a hearing

The Subcommittee on Regulatory Reform, Commercial and Antitrust Law holds a hearing entitled, "Competition in the Pharmaceutical Supply Chain: The Proposed Merger of CVS Health and Aetna" with Thomas Moriarty, EVP of CVS Health and Thomas Sabatino, EVP of Aetna on February 27 at 1:30 pm. Webcast Link

AET

Aetna

$177.00

1.25 (0.71%)

CVS

CVS Health

$68.64

0.41 (0.60%)

  • 27

    Feb

  • 16

    Apr

  • 30

    May

AET Aetna
$177.00

1.25 (0.71%)

02/01/18
02/01/18
DOWNGRADE
Target $69

Underperform
Express Scripts downgraded to Underperform at Bernstein
As previously reported, Bernstein analyst Lance Wilkes downgraded Express Scripts to Underperform from Market Perform, with a $69 price target, as he believes tax reform is fully price in and his original concerns on the standalone PBM model remain. Further, the analyst sees additional risks from a potential CVS (CVS)/Aetna (AET) merger and Amazon (AMZN) threats.
01/31/18
FBCO
01/31/18
NO CHANGE
Target $208
FBCO
Neutral
Aetna price target raised to $208 from $200 at Credit Suisse
Credit Suisse analyst A.J. Rice raised his price target for Aetna to $208 from $200, citing on track operationally. However, the analyst is cautious on sustainability of tax benefit. He reiterates a Neutral rating on the shares.
01/31/18
RBCM
01/31/18
UPGRADE
Target $98
RBCM
Outperform
Express Scripts upgraded to Outperform at RBC Capital
As reported earlier, RBC Capital analyst George Hill upgraded Express Scripts (ESRX) to Outperform and raised his price target to $98 from $68. Hill cites the "recent sharp pullback on Amazon's (AMZN) healthcare entry" de-risking the stock, while also pointing to the trend of vertical integration as seen in the CVS (CVS)-Aetna (AET) deal. The analyst believes Express Scripts could also become an attractive M&A target as "one of the few remaining assets at scale".
01/31/18
PIPR
01/31/18
NO CHANGE
Target $212
PIPR
Overweight
Piper sees buying opportunity in Aetna after yesterday's pullback
Piper Jaffray analyst Sarah James sees a buying opportunity in Aetna (AET) following yesterday's 3% pullback on the Amazon (AMZN), Berkshire (BRK.A) and JPMorgan (JPM) news. The company yesterday morning posted a solid earnings beat driven by strong cost trend management in the government and commercial businesses, James tells investors in a research note. She raised her price target for Aetna shares to $212 from $207 and keeps an Overweight rating on the name. CVS Health's (CVS) takeout offer now values the shares at $212, up from $207 previously, based on 0.8378 shares of CVS stock plus $145 per share in cash, James points out. The analyst sees a "win-win" setup for the stock based on the deal going through or the company remaining standalone.
CVS CVS Health
$68.64

0.41 (0.60%)

02/27/18
BOFA
02/27/18
INITIATION
Target $91
BOFA
Buy
CVS Health reinstated with a Buy at BofA/Merrill
BofA/Merrill analyst Michael Cherny reinstated coverage on CVS Health with a Buy and $91 price target.
02/14/18
JEFF
02/14/18
NO CHANGE
JEFF
Amazon focusing on bolstering medical device distribution, says Jefferies
Yesterday's Wall Street Journal report and a recent scan of job postings still point to Amazon.com's (AMZN) focus on bolstering its medical device/supplies distribution capabilities, specifically targeting hospitals, Jefferies analyst Brian Tanquilut. These postings support a negative thesis for Cardinal Health (CAH), Owens & Minor (OMI) and Premier's (PINC) medical supplies businesses, the analyst adds. Further, he sees the news as an incremental positive for AmerisourceBergen (ABC), McKesson (MCK), CVS Health (CVS) and Walgreens Boots Alliance (WBA) since it further supports the view that Amazon isn't looking to enter the prescription business near-term.
02/09/18
NEED
02/09/18
NO CHANGE
Target $98
NEED
Strong Buy
CVS Health price target lowered to $98 after earnings at Needham
Needham analyst Kevin Caliendo lowered his price target on CVS Health to $98 from $100 after the company's earnings. Caliendo notes that while the PBM and retail businesses were solid, the negative development of CVS planning to reinvest $1.2B of tax reform windfall in compensation and infrastructure "undermined the positives". The analyst is also concerned with President Trump's budget proposal focusing on curbing drug prices. However, he maintains a Strong Buy rating on CVS shares.
02/09/18
MACQ
02/09/18
NO CHANGE
Target $88
MACQ
Outperform
CVS Health shares are cheap with 'huge' potential, says Macquarie
Macquarie analyst Bob Summers said CVS (CVS) reported a beat on both the top and bottom line for Q4, but lowered adjusted operating profit growth to down 1.5% to up 1.5%, from 1-4% growth, announced investments, funded from lower tax rates, which will create a 250 bps headwind in FY18. Summers remains constructive noting total same-store-sales were positive for the first time in five quarters and believes shares are over-discounting weak operating trends and the threat of Amazon (AMZN) entering a highly regulated market. The analyst rates CVS an Outperform with an $88 price target.

TODAY'S FREE FLY STORIES

JBHT

J.B. Hunt

$120.99

-0.78 (-0.64%)

14:08
07/16/18
07/16
14:08
07/16/18
14:08
Recommendations
J.B. Hunt analyst commentary  »

Loop says J.B. Hunt…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Aug

SYRS

Syros Pharmaceuticals

$12.35

(0.00%)

14:08
07/16/18
07/16
14:08
07/16/18
14:08
Conference/Events
Syros Pharmaceuticals to hold a key opinion leader meeting »

Key Opinion Leader…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

EQGP

EQT GP

$24.87

-0.25 (-1.00%)

, EQM

EQT Midstream Partners

$54.90

0.49 (0.90%)

14:02
07/16/18
07/16
14:02
07/16/18
14:02
Conference/Events
Rice Midstream to host special shareholder meeting »

Special Shareholder…

EQGP

EQT GP

$24.87

-0.25 (-1.00%)

EQM

EQT Midstream Partners

$54.90

0.49 (0.90%)

RMP

Rice Midstream

$18.16

0.16 (0.89%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jul

  • 26

    Jul

CRSP

Crispr Therapeutics

$59.61

-6.13 (-9.32%)

14:01
07/16/18
07/16
14:01
07/16/18
14:01
Periodicals
Crispr Therapeutics tells CNBC does not use methods described in paper »

Crispr Therapeutics told…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MAS

Masco

$37.79

-0.22 (-0.58%)

14:00
07/16/18
07/16
14:00
07/16/18
14:00
Options
Bullish option play opened in Masco ahead of earnings »

Bullish option play…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Jul

CRSP

Crispr Therapeutics

$59.09

-6.65 (-10.12%)

13:55
07/16/18
07/16
13:55
07/16/18
13:55
Options
Crispr Therapeutics put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

13:50
07/16/18
07/16
13:50
07/16/18
13:50
General news
U.S. equities are up from earlier lows »

U.S. equities are up from…

ECA

Encana

$12.84

-0.4 (-3.02%)

13:45
07/16/18
07/16
13:45
07/16/18
13:45
Options
Encana call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Aug

  • 09

    Oct

ADS

Alliance Data

$220.17

-23.32 (-9.58%)

13:44
07/16/18
07/16
13:44
07/16/18
13:44
Technical Analysis
Technical Take: Alliance Data comes off the lows of the day »

Shares were last down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jul

  • 08

    Aug

CRM

Salesforce

$147.50

-0.18 (-0.12%)

13:39
07/16/18
07/16
13:39
07/16/18
13:39
Hot Stocks
Salesforce announces definitive agreement to acquire Datorama »

Salesforce has signed a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

  • 16

    Aug

YELP

Yelp

$40.33

0.54 (1.36%)

13:35
07/16/18
07/16
13:35
07/16/18
13:35
Options
Yelp put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LBIX

Leading Brands

$1.62

-0.06 (-3.57%)

13:32
07/16/18
07/16
13:32
07/16/18
13:32
Hot Stocks
Leading Brands announces resolution of temporary non-compliance with Nasdaq rule »

Leading Brands announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

STM

STMicroelectronics

$22.84

0.2 (0.88%)

13:25
07/16/18
07/16
13:25
07/16/18
13:25
Options
STMicroelectronics call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

13:25
07/16/18
07/16
13:25
07/16/18
13:25
Conference/Events
Stephens agricultural analyst to hold an analyst/industry conference call »

Agriculture, Chemicals,…

EDIT

Editas Medicine

$36.20

-1.71 (-4.51%)

, NTLA

Intellia Therapeutics

$30.55

-2.05 (-6.29%)

13:23
07/16/18
07/16
13:23
07/16/18
13:23
Periodicals
Editas tells CNBC 'not specifically concerned about' Crisper study »

Editas Medicine (EDIT)…

EDIT

Editas Medicine

$36.20

-1.71 (-4.51%)

NTLA

Intellia Therapeutics

$30.55

-2.05 (-6.29%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CVS

CVS Health

$68.30

-0.33 (-0.48%)

13:19
07/16/18
07/16
13:19
07/16/18
13:19
Periodicals
CVS apologizes after store managers call police on black customer, AP says »

CVS Health is apologizing…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

13:17
07/16/18
07/16
13:17
07/16/18
13:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

13:16
07/16/18
07/16
13:16
07/16/18
13:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PEGI

Pattern Energy

$17.84

0.75 (4.39%)

13:10
07/16/18
07/16
13:10
07/16/18
13:10
Options
Change of sentiment in Pattern Energy »

Change of sentiment in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

13:05
07/16/18
07/16
13:05
07/16/18
13:05
Conference/Events
The Brookings Institution to hold a conference »

7th Annual Municipal…

C

Citi

$69.22

2.22 (3.31%)

13:04
07/16/18
07/16
13:04
07/16/18
13:04
Hot Stocks
Citi reports June credit loss 2.60% vs. 2.78% last month »

Reports June 30-plus day…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jul

  • 14

    Jan

  • 15

    Apr

  • 13

    Jul

  • 15

    Oct

ORMP

Oramed

$5.89

-0.08 (-1.34%)

13:02
07/16/18
07/16
13:02
07/16/18
13:02
Downgrade
Oramed rating change  »

B. Riley FBR downgrades…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

QDEL

Quidel

$69.21

0.03 (0.04%)

13:01
07/16/18
07/16
13:01
07/16/18
13:01
Hot Stocks
Quidel receives FDA clearance to market Solana Bordetella Complete Assay »

Quidel announced that it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RRD

R.R. Donnelley

$5.53

-0.11 (-1.95%)

13:00
07/16/18
07/16
13:00
07/16/18
13:00
Options
4K RR Donnelley and Sons Aug 6 calls trade for 24c »

4K RR Donnelley and Sons…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

13:00
07/16/18
07/16
13:00
07/16/18
13:00
General news
Fed Chairman Powell's Monetary Policy testimony Tuesday won't break new ground »

Fed Chairman…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.